Systemic Mastocytosis

Hematology/Oncology Clinics of North America

Volumn 25, Issue 5, 2011, Pages 1067-1083

  George, Tracy I ^a   Horny, Hans Peter ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Klinikum Ansbach   (Germany)

Author keywords

KIT D816V; Mast cell; Mast cell leukemia; Systemic mastocytosis

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CORTICOSTEROID; IMATINIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; CELL HYPERPLASIA; CYTOLOGY; CYTOREDUCTIVE SURGERY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; FLUSHING; HEADACHE; HISTOLOGY; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MAST CELL CYTOLOGY; MAST CELL HYPERPLASIA; MAST CELL LEUKEMIA; MUSCULOSKELETAL DISEASE; MYELOID LEUKEMIA; MYELOMASTOCYTIC LEUKEMIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SKIN DEFECT; SYNCOPE; SYSTEMIC MASTOCYTOSIS; TISSUE SECTION;

AMINO ACID SUBSTITUTION; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; WORLD HEALTH ORGANIZATION;

EID: 80755189387     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.09.012     Document Type: Review

References (32)

1. Horny H.P. Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol 2009, 132(3):438-447.
2. Horny H.P., Akin C., Metcalfe D.D., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (France) 2008, 53-63. IARC Press. S. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Valent P., Sperr W.R., Schwartz L.B., et al. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004, 114(1):3-11.
4. Horny H.P., Parwaresch M.R., Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985, 16(8):808-814.
5. Horny H.P., Sotlar K., Valent P. Mastocytosis: state of the art. Pathobiology 2007, 74(2):121-132.
6. Valent P., Samorapoompichi P., Sperr W.R., et al. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002, 3(2):90-94.
7. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
8. Krokowski M., Sotlar K., Krauth M.T., et al. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariations of the disease and separation from mast cell hyperplasia. Am J Clin Pathol 2005, 124(4):560-568.
9. Horny H.P., Sotlar K., Stellmacher F., et al. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 2006, 59(3):298-302.
10. Sperr W.R., Horny H.P., Lechner K., et al. Clinical and biological diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000, 37(5-6):473-486.
11. Sotlar K., Horny H.P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004, 28(10):1319-1325.
12. Escribano L., Diaz-Agustin B., López A., et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA). Cytometry B Clin Cytom 2004, 58(1):1-8.
13. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108(7):2366-2372.
14. Feger F., Ribadeau D.A., Lerich L., et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002, 127(2):110-114.
15. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130(3):804-815.
16. Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008, 53(3):245-266.
17. Beghini A., Ripamonti C.B., Cairoli R., et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004, 89(8):920-925.
18. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348(13):1201-1214.
19. Bain B.J., Fletcher S.H. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007, 27(3):377-388.
20. Sperr W.R., Jordan J.H., Baghestanian M., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98(7):2200-2209.
21. Arredondo A., Gotlib J., Shier L., et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol 2010, 85(8):600-606.
22. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102(9):3093-3096.
23. Rywlin A.M., Hoffman E.P., Ortega R.S. Eosinophilic fibrohistiocytic lesion of bone marrow: a distinctive new morphologic finding, probably related to drug hypersensitivity. Blood 1972, 40(4):464-472.
24. Akin C., Fumo G., Akif S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103(8):3222-3225.
25. Frieri M., Linn N., Schweitzer M., et al. Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy. J Allergy Clin Immunol 1990, 86(1):126-132.
26. Noack F., Sotlar K., Notter M., et al. A leukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma 2004, 45(11):2295-2302.
27. Valentini C.G., Rondoni M., Pogliani E.M., et al. Mast cell leukemia: a report of ten cases. Ann Hematol 2008, 87(16):505-508.
28. Sperr W.R., Drach J., Hauswirth A.W., et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005, 11(19 Pt 1):6787-6792.
29. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99(5):1741-1744.
30. Gotlib J., Berube C., Growney J.D., et al. Activity of tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106(8):2865-2870.
31. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14(12):3906-3915.
32. Ustun C., Corless C.L., Savage N., et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 2009, 33(5):735-741.